Weight Management

MariTide

AMG 133 · AMG-133 · maritide

Amgen investigational antibody-peptide conjugate (AMG 133 / MariTide): GIP receptor antagonist plus GLP-1 receptor agonism, studied on a monthly-class schedule in obesity programs. Not an FDA-approved pen. Not a lyophilized research cake interchangeable with Wegovy or Zepbound.

Not FDA-approved - research chemical

Reviewed by CalcMyPeptide Editorial Team

·Last updated: September 2026·Evidence: Emerging

Typical research dose

Investigational - sponsor protocol only

Frequency

Monthly-class in Amgen program (not a research cake)

Half-life

Monthly-class program (sponsor PK; not a research-cake t½)

Common vials

N/A (oral)

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Metabolic / weight6.5/10
Large obesity program interest. Ceiling for Phase 2–3 investigational; haircut because there is no finished US pen and gray-market fill is not AMG 133.

Compound card

Sequence: Antibody–peptide conjugate (AMG 133 / MariTide; not a simple lyophilized 15-mer)
Class: Investigational monthly-class GIPR antagonist + GLP-1R agonist (Amgen)
Formula: Antibody-peptide conjugate (proprietary)
Status: Not FDA-approved · research use

How it works

MariTide (AMG 133) is Amgen’s investigational construct that pairs GIP receptor antagonism with GLP-1 receptor agonism. The public development story is monthly-class obesity dosing under sponsor protocols — not a weekly twincretin pen and not a research-chem cake you reconstitute like BPC-157.

Identity job on this leaf: keep MariTide distinct from semaglutide, tirzepatide, retatrutide, and CagriSema. Mechanism class is dual pathway (GIPR block + GLP-1R agonism), not “another GLP-1.”

Source: Amgen clinical program disclosures (AMG 133 / MariTide); not a finished US label

Research Use Cases

✓Obesity pipeline literacy: Moderate
✓Research-chem reconstitution: Low

Dosing

Phase	Dose	Frequency	Notes
Human care	Sponsor protocol only	Monthly-class in Amgen program	Not a cake. Not a compounded weekly twincretin.
Research-chem SKU	Do not invent	n/a	If a vendor sells “MariTide,” identity is unverified. Skip the reconstitution calculator.

Administration

Route / form

Parenteral under clinical protocol (not a home reconstitution pen)

Timing

Program-defined

Empty stomach?

No - Food timing is not critical.

Timeline

Trial programs

Obesity endpoints are sponsor-owned. There is no community week-1 folklore to launder onto a gray vial.

Who it is for

Obesity pipeline literacy

Moderate

Worth knowing the name and mechanism class. Not a DIY protocol.

Research-chem reconstitution

Low

Wrong tool. Wrong product class.

Safety & Considerations

Investigational. GI class effects are expected for GLP-1-pathway agents. Unverified research vials are a separate product-identity risk. Not for pregnancy. Same class cautions as other incretin programs until a label exists.

Regulatory & Legal Status

FDA Status (US)

Research Only

WADA Status (2026)

Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

No finished US obesity label on this leaf’s date.
Sponsor protocol milligrams are not a research-chem dosing table.
Not interchangeable with tirzepatide (GIP agonist) or retatrutide (triple agonist).
This site will not treat obesity from an investigational leaf.

Verdict

MariTide is Amgen’s monthly-class GIPR-antagonist / GLP-1 agonist program. It is not Wegovy, not Zepbound, and not a lyophilized research cake. Do not invent a reconstitution chart for a molecule you cannot confirm on a COA.

Interactions & Contraindications

Appears in goal guides

Goal guides are maps, not clinic protocols. A mention here is not a treatment plan.

Precision Fat Loss & Metabolic Reset

Labeled incretin and dual-agonist pens (STEP, SURMOUNT) versus research cakes, plus GHRH VAT math. Percentages are branded-trial numbers, not a compounded vial.

View Protocol →